Merck KGaA’s Erbitux fails in colon cancer study

FRANKFURT (Reuters) - Germany's Merck KGaA said on Wednesday that Erbitux, one of its most important drugs, failed to help colon cancer patients after surgery in a late stage trial.
Read the full story: Reuters: Health News